View Older Stories View More Recent Stories

Aug 7, 2019 08:44PM Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee’s Recommendation on Descovy for PrEP™
Aug 6, 2019 08:00AM Ontario Provides Access to Biktarvy® for the Treatment of HIV
Jul 30, 2019 04:02PM Gilead Sciences Announces Third Quarter 2019 Dividend
Jul 23, 2019 04:00PM Gilead Sciences (GILD) Reports Latest Data in Ongoing HIV Cure Research Program
Jul 23, 2019 04:00PM Gilead Announces Latest Data in Ongoing HIV Cure Research Program
Jul 23, 2019 11:02AM Gilead Sciences (GILD) Presents New Findings on Profile of Descovy for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada
Jul 23, 2019 11:00AM Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®
Jul 22, 2019 12:01PM Gilead Sciences (GILD) Presents New Data on Biktarvy for Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance
Jul 22, 2019 12:00PM Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance
Jul 22, 2019 11:01AM Gilead Sciences (GILD) Presents Proof-of-Concept Data for GS-6207 in People with HIV
Jul 22, 2019 11:00AM Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV
Jul 18, 2019 08:36AM Gilead Sciences (GILD) to Present New Data on HIV Prevention, Treatment and Cure Research at IAS
Jul 18, 2019 08:30AM Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019
Jul 17, 2019 08:33AM Gilead Sciences (GILD) Announces Chief Scientific Officer John McHutchison to Leave Company
Jul 17, 2019 08:31AM Gilead Sciences (GILD) Announces Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing
Jul 17, 2019 08:30AM Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company
Jul 17, 2019 08:30AM Gilead Sciences Announces Changes to Senior Leadership Team
Jul 16, 2019 04:05PM Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019
Jul 16, 2019 08:30AM Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
Jul 11, 2019 04:31PM Gilead Sciences (GILD) Appoints Christi L. Shaw as CEO of Kite
Jul 11, 2019 04:30PM Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite
Jul 11, 2019 08:30AM Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)
Jul 2, 2019 06:42AM Gilead Sciences (GILD) to Submit Filgotinib NDA This Year
Jul 1, 2019 07:00PM Gilead Announces Intent to Submit New Drug Application for Filgotinib to U.S. Food and Drug Administration This Year
Jun 26, 2019 11:30AM Louisiana Launches Hepatitis C Innovative Payment Model With Asegua Therapeutics, Aiming to Eliminate the Disease
Jun 3, 2019 09:00AM Kite Announces New Yescarta® Data From ZUMA-1
Jun 3, 2019 05:52AM Gilead Sciences (GILD) Subsidiary Kite Reports End of Phase 1 ZUMA-3 Results for KTE-X19 at ASCO 2019 Meetings
Jun 1, 2019 06:00PM Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
May 29, 2019 08:31AM Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer
May 21, 2019 04:01PM Gilead Sciences to Present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5
May 15, 2019 05:00PM Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019
May 9, 2019 05:11PM Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic
May 6, 2019 04:01PM Gilead Sciences to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14
May 2, 2019 04:02PM Gilead Sciences Announces Second Quarter 2019 Dividend
Apr 30, 2019 04:27PM Gilead Sciences (GILD) CFO Robin Washington to Step Down in Early 2020
Apr 30, 2019 04:27PM Gilead Sciences’ Chief Financial Officer Robin Washington to Step Down in Early 2020
Apr 25, 2019 08:01AM Gilead Sciences (GILD) Reports Topline Data from Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)
Apr 25, 2019 08:00AM Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)
Apr 24, 2019 08:30AM Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities
Apr 18, 2019 04:05PM Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019
Apr 16, 2019 07:01AM Gilead Sciences (GILD), insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for NASH
Apr 16, 2019 07:00AM Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis
Apr 12, 2019 06:31AM Gilead Sciences (GILD), Novo Nordisk (NVO) Announce Intent to Initiate a Clinical Collaboration in NASH
Apr 12, 2019 04:00AM Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH
Apr 11, 2019 09:18AM Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019
Apr 11, 2019 02:00AM Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019
Apr 9, 2019 12:00PM Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases
Apr 5, 2019 08:31AM Gilead Sciences (GILD) Submits sNDA to FDA for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
Apr 5, 2019 08:30AM Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
Mar 28, 2019 05:00AM Gilead Launches HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia
View More Recent Stories View Older Stories